- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5 ; volume:2 ; number:1 ; day:8 ; month:12 ; year:2005 ; pages:1 ; date:12.2005
Retrovirology ; 2, Heft 1 (8.12.2005), 1, 12.2005
- Contributor
-
Demarest, James F.
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-2-S1-S13
- URN
-
urn:nbn:de:1111-2016080653570
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Demarest, James F.
- SpringerLink (Online service)
Other Objects (12)
Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5
Clinical use of CCR5 inhibitors in HIV and beyond
HIV-1 Escape From Small Molecule CCR5 Inhibitors In Vitro
Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders
Entry inhibitors in HIV therapy
Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor
Lysosomotropic agents as HCV entry inhibitors
Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis
Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro
Peptides targeting caspase inhibitors
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5
Clinical use of CCR5 inhibitors in HIV and beyond
HIV-1 Escape From Small Molecule CCR5 Inhibitors In Vitro
Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders
Entry inhibitors in HIV therapy
Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor
Lysosomotropic agents as HCV entry inhibitors
Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis
Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro
Peptides targeting caspase inhibitors
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5
Clinical use of CCR5 inhibitors in HIV and beyond
HIV-1 Escape From Small Molecule CCR5 Inhibitors In Vitro
Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders
Entry inhibitors in HIV therapy
Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor
Lysosomotropic agents as HCV entry inhibitors
Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis
Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro
Peptides targeting caspase inhibitors